Opinion

What are the risks of future 'pay for delay' settlements between branded and generic manufacturers?

Regardless of how pending US legislation is resolved, manufacturers need to move ahead

Life sciences companies - including mid-market ones - are finding value in an outsourced service

The full range of healthcare manufacturers should have a unified voice

Continuing problems with compounding pharmacies muddle biopharma’s future direction

Oncology is the market for today's pipeline products. Here's why the community setting needs to be preserved as a primary site of care to administer those products

In the race to improve product performance, not enough attention is paid to 'who's actually going to switch?'

Like the other war on drugs, there's no end in sight

When drugs in development today hit the marketplace in 2020, they will need evidence of economic and clinical value results to be commercially successful

Pharmaceutical marketing is now operating in a new landscape--the Economy of Attention

Abbott's spinout of AbbVie offers lessons

Applying the managed services model to commercial operations can result in dramatic savings as pharma companies globalize

The USP standard, currently in draft form, is an effort to provide recommendations for end-to-end supply chain integrity

Industry is not waiting for action in Washington

Prospects for international policing of counterfeit drugs is dim

Modernized packaging technologies can change the drug-distribution dynamic - and improve overall healthcare

Tomorrow's healthcare market, driven by consumer choice and outcomes-driven economics, will create new supply chain models

Merger is not expected to affect specialty-distribution agreements negatively

Ten-year BLS projection sees a healthy industry ahead

FDA's draft documents on biosimilar regulation move the prospect one step closer